Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Interplay of chemical and thermal gradient on bacterial migration in a diffusive microfluidic device.

Murugesan N, Dhar P, Panda T, Das SK.

Biomicrofluidics. 2017 Mar 24;11(2):024108. doi: 10.1063/1.4979103. eCollection 2017 Mar.

2.

Health education on diabetes and other non-communicable diseases imparted to teachers shows a cascading effect. A study from Southern India.

Selvam S, Murugesan N, Snehalatha C, Nanditha A, Raghavan A, Simon M, Susairaj P, Ramachandran A.

Diabetes Res Clin Pract. 2017 Mar;125:20-28. doi: 10.1016/j.diabres.2017.01.004. Epub 2017 Jan 17.

PMID:
28131070
3.

Effect of gold nanoparticles on thermal gradient generation and thermotaxis of E. coli cells in microfluidic device.

Murugesan N, Panda T, Das SK.

Biomed Microdevices. 2016 Aug;18(4):53. doi: 10.1007/s10544-016-0077-8.

PMID:
27246690
4.

Plasma Kallikrein Mediates Vascular Endothelial Growth Factor-Induced Retinal Dysfunction and Thickening.

Clermont A, Murugesan N, Zhou Q, Kita T, Robson PA, Rushbrooke LJ, Evans DM, Aiello LP, Feener EP.

Invest Ophthalmol Vis Sci. 2016 May 1;57(6):2390-9. doi: 10.1167/iovs.15-18272.

5.

E. coli DH5α cell response to a sudden change in microfluidic chemical environment.

Murugesan N, Panda T, Das SK.

Conf Proc IEEE Eng Med Biol Soc. 2015;2015:3213-6. doi: 10.1109/EMBC.2015.7319076.

PMID:
26736976
6.

Spontaneous nontraumatic subarachnoid hemorrhage without cerebrovascular malformations in a maintenance hemodialysis patient.

Jayasurya R, Murugesan N, Kumar R, Dubey AK, Priyamvada PS, Swaminathan RP, Parameswaran S.

Indian J Nephrol. 2015 Sep-Oct;25(5):310-4. doi: 10.4103/0971-4065.156909.

7.

Thrombosis and Hemorrhage in Diabetic Retinopathy: A Perspective from an Inflammatory Standpoint.

Murugesan N, Üstunkaya T, Feener EP.

Semin Thromb Hemost. 2015 Sep;41(6):659-64. doi: 10.1055/s-0035-1556731. Epub 2015 Aug 25. Review.

8.

Plasma Kallikrein-Kinin System as a VEGF-Independent Mediator of Diabetic Macular Edema.

Kita T, Clermont AC, Murugesan N, Zhou Q, Fujisawa K, Ishibashi T, Aiello LP, Feener EP.

Diabetes. 2015 Oct;64(10):3588-99. doi: 10.2337/db15-0317. Epub 2015 May 15.

9.

Extragastrointestinal stromal tumour of the abdominal wall - a case report.

Kumar AS, Padmini R, Veena G, Murugesan N.

J Clin Diagn Res. 2013 Dec;7(12):2970-2. doi: 10.7860/JCDR/2013/7863.3812. Epub 2013 Dec 15.

10.

Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties.

Ellsworth BA, Sher PM, Wu X, Wu G, Sulsky RB, Gu Z, Murugesan N, Zhu Y, Yu G, Sitkoff DF, Carlson KE, Kang L, Yang Y, Lee N, Baska RA, Keim WJ, Cullen MJ, Azzara AV, Zuvich E, Thomas MA, Rohrbach KW, Devenny JJ, Godonis HE, Harvey SJ, Murphy BJ, Everlof GG, Stetsko PI, Gudmundsson O, Johnghar S, Ranasinghe A, Behnia K, Pelleymounter MA, Ewing WR.

J Med Chem. 2013 Dec 12;56(23):9586-600. doi: 10.1021/jm4010835. Epub 2013 Nov 20.

PMID:
24182233
11.

Active induction of experimental autoimmune encephalomyelitis by MOG35-55 peptide immunization is associated with differential responses in separate compartments of the choroid plexus.

Murugesan N, Paul D, Lemire Y, Shrestha B, Ge S, Pachter JS.

Fluids Barriers CNS. 2012 Aug 7;9(1):15. doi: 10.1186/2045-8118-9-15.

12.

Rapid expression profiling of brain microvascular endothelial cells by immuno-laser capture microdissection coupled to TaqMan(®) low density array.

Demarest TG, Murugesan N, Shrestha B, Pachter JS.

J Neurosci Methods. 2012;206(2):200-4. doi: 10.1016/j.jneumeth.2012.02.023. Epub 2012 Mar 10.

13.

Brain regional angiogenic potential at the neurovascular unit during normal aging.

Murugesan N, Demarest TG, Madri JA, Pachter JS.

Neurobiol Aging. 2012 May;33(5):1004.e1-16. doi: 10.1016/j.neurobiolaging.2011.09.022. Epub 2011 Oct 21.

14.

Characterization of a novel and selective CB1 antagonist as a radioligand for receptor occupancy studies.

Yang Y, Miller KJ, Zhu Y, Hong Y, Tian Y, Murugesan N, Gu Z, O'Tanyi E, Keim WJ, Rohrbach KW, Johnghar S, Behnia K, Pelleymounter MA, Carlson KE, Ewing WR.

Bioorg Med Chem Lett. 2011 Nov 15;21(22):6856-60. doi: 10.1016/j.bmcl.2011.09.016. Epub 2011 Sep 13.

PMID:
21962575
15.

Probing the CNS microvascular endothelium by immune-guided laser-capture microdissection coupled to quantitative RT-PCR.

Murugesan N, Macdonald J, Ge S, Pachter JS.

Methods Mol Biol. 2011;755:385-94. doi: 10.1007/978-1-61779-163-5_32.

PMID:
21761321
16.

Analysis of mouse brain microvascular endothelium using laser capture microdissection coupled with proteomics.

Murugesan N, Macdonald JA, Lu Q, Wu SL, Hancock WS, Pachter JS.

Methods Mol Biol. 2011;686:297-311. doi: 10.1007/978-1-60761-938-3_14.

PMID:
21082378
17.

The study of mitral valve annular dimension in relation to the body surface area in the Indian population.

Rajila Rajendran HS, Seshayyan S, Victor A, Murugesan N, Sundaramurthi I.

Eur J Cardiothorac Surg. 2011 May;39(5):653-6. doi: 10.1016/j.ejcts.2010.08.052. Epub 2010 Oct 12.

PMID:
20943411
18.

Endothelial cell heterogeneity of blood-brain barrier gene expression along the cerebral microvasculature.

Macdonald JA, Murugesan N, Pachter JS.

J Neurosci Res. 2010 May 15;88(7):1457-74. doi: 10.1002/jnr.22316.

PMID:
20025060
19.

Astrocyte- and endothelial-targeted CCL2 conditional knockout mice: critical tools for studying the pathogenesis of neuroinflammation.

Ge S, Murugesan N, Pachter JS.

J Mol Neurosci. 2009 Sep;39(1-2):269-83. doi: 10.1007/s12031-009-9197-4. Epub 2009 Apr 2.

20.

Immediate impact of a diabetes training programme for primary care physicians--an endeavour for national capacity building for diabetes management in India.

Murugesan N, Shobana R, Snehalatha C, Kapur A, Ramachandran A.

Diabetes Res Clin Pract. 2009 Jan;83(1):140-4. doi: 10.1016/j.diabres.2008.11.005. Epub 2008 Dec 17.

PMID:
19095326
21.

Population based study of quality of diabetes care in southern India.

Ramachandran A, Mary S, Sathish CK, Selvam S, Catherin Seeli A, Muruganandam M, Yamuna A, Murugesan N, Snehalatha C.

J Assoc Physicians India. 2008 Jul;56:513-6.

PMID:
18846902
22.

Synthesis and in vivo evaluation of novel PET radioligands for imaging the endothelin-A receptor.

Mathews WB, Murugesan N, Xia J, Scheffel U, Hilton J, Ravert HT, Dannals RF, Szabo Z.

J Nucl Med. 2008 Sep;49(9):1529-36. doi: 10.2967/jnumed.108.051565. Epub 2008 Aug 14.

23.

Validation of immuno-laser capture microdissection coupled with quantitative RT-PCR to probe blood-brain barrier gene expression in situ.

Macdonald JA, Murugesan N, Pachter JS.

J Neurosci Methods. 2008 Sep 30;174(2):219-26. doi: 10.1016/j.jneumeth.2008.07.009. Epub 2008 Jul 23.

PMID:
18692089
24.

Analysis of mouse brain microvascular endothelium using immuno-laser capture microdissection coupled to a hybrid linear ion trap with Fourier transform-mass spectrometry proteomics platform.

Lu Q, Murugesan N, Macdonald JA, Wu SL, Pachter JS, Hancock WS.

Electrophoresis. 2008 Jun;29(12):2689-95. doi: 10.1002/elps.200700936.

PMID:
18481836
25.

High prevalence of cardiometabolic risk factors among young physicians in India.

Ramachandran A, Snehalatha C, Yamuna A, Murugesan N.

J Assoc Physicians India. 2008 Jan;56:17-20.

PMID:
18472494
26.

High prevalence of diabetes and cardiovascular risk factors associated with urbanization in India.

Ramachandran A, Mary S, Yamuna A, Murugesan N, Snehalatha C.

Diabetes Care. 2008 May;31(5):893-8. doi: 10.2337/dc07-1207. Epub 2008 Feb 29.

PMID:
18310309
27.

Design and SAR of selective T-type calcium channel antagonists containing a biaryl sulfonamide core.

Hangeland JJ, Cheney DL, Friends TJ, Swartz S, Levesque PC, Rich AJ, Sun L, Bridal TR, Adam LP, Normandin DE, Murugesan N, Ewing WR.

Bioorg Med Chem Lett. 2008 Jan 15;18(2):474-8. Epub 2007 Dec 3.

PMID:
18160281
28.

Insulin resistance and clustering of cardiometabolic risk factors in urban teenagers in southern India.

Ramachandran A, Snehalatha C, Yamuna A, Murugesan N, Narayan KM.

Diabetes Care. 2007 Jul;30(7):1828-33. Epub 2007 Apr 6.

PMID:
17416794
29.

Reduction of site-specific CYP3A-mediated metabolism for dual angiotensin and endothelin receptor antagonists in various in vitro systems and in cynomolgus monkeys.

Zhang H, Zhang D, Li W, Yao M, D'Arienzo C, Li YX, Ewing WR, Gu Z, Zhu Y, Murugesan N, Shyu WC, Humphreys WG.

Drug Metab Dispos. 2007 May;35(5):795-805. Epub 2007 Feb 15.

PMID:
17303626
30.

Awareness about diabetes and its complications in the general and diabetic population in a city in southern India.

Murugesan N, Snehalatha C, Shobhana R, Roglic G, Ramachandran A.

Diabetes Res Clin Pract. 2007 Sep;77(3):433-7. Epub 2007 Feb 8.

PMID:
17291622
31.

Increasing expenditure on health care incurred by diabetic subjects in a developing country: a study from India.

Ramachandran A, Ramachandran S, Snehalatha C, Augustine C, Murugesan N, Viswanathan V, Kapur A, Williams R.

Diabetes Care. 2007 Feb;30(2):252-6.

PMID:
17259490
32.

Reader's perspectives..."Outsourced I.T. services are better run than those that remain managed in-house. Do you agree or disagree"?

Thompson C, Duffy W, Turnbull B, Murugesan N, McCormick M, Allan E, Brown M.

Health Data Manag. 2006 Sep;14(9):72. No abstract available.

PMID:
17009591
33.

Tryptamine and homotryptamine-based sulfonamides as potent and selective inhibitors of 15-lipoxygenase.

Weinstein DS, Liu W, Gu Z, Langevine C, Ngu K, Fadnis L, Combs DW, Sitkoff D, Ahmad S, Zhuang S, Chen X, Wang FL, Loughney DA, Atwal KS, Zahler R, Macor JE, Madsen CS, Murugesan N.

Bioorg Med Chem Lett. 2005 Mar 1;15(5):1435-40.

PMID:
15713402
34.

Community mobilisation for leprosy elimination.

Murugesan N.

Indian J Lepr. 2004 Apr-Jun;76(2):166-9. No abstract available.

PMID:
15648431
35.

Dual angiotensin II and endothelin A receptor antagonists: synthesis of 2'-substituted N-3-isoxazolyl biphenylsulfonamides with improved potency and pharmacokinetics.

Murugesan N, Gu Z, Fadnis L, Tellew JE, Baska RA, Yang Y, Beyer SM, Monshizadegan H, Dickinson KE, Valentine MT, Humphreys WG, Lan SJ, Ewing WR, Carlson KE, Kowala MC, Zahler R, Macor JE.

J Med Chem. 2005 Jan 13;48(1):171-9.

PMID:
15634011
36.

Some suggestions for implementing rehabilitation of leprosy-affected persons in Tamil Nadu.

Murugesan N.

Indian J Lepr. 2003 Apr-Jun;75(2):189-95. Review. No abstract available.

PMID:
15255405
37.

Novel dual action AT1 and ETA receptor antagonists reduce blood pressure in experimental hypertension.

Kowala MC, Murugesan N, Tellew J, Carlson K, Monshizadegan H, Ryan C, Gu Z, Kane B, Fadnis L, Baska RA, Beyer S, Arthur S, Dickinson K, Zhang D, Perrone M, Ferrer P, Giancarli M, Baumann J, Bird E, Panchal B, Yang Y, Trippodo N, Barrish J, Macor JE.

J Pharmacol Exp Ther. 2004 Apr;309(1):275-84. Epub 2004 Jan 12.

PMID:
14718594
38.

Application of structure-metabolism relationships in the identification of a selective endothelin A antagonist, BMS-193884, with favourable pharmacokinetic properties.

Humphreys WG, Obermeier MT, Barrish JC, Chong S, Marino AM, Murugesan N, Wang-Iverson D, Morrison RA.

Xenobiotica. 2003 Nov;33(11):1109-23.

PMID:
14660175
39.

Discovery of 4'-[(imidazol-1-yl)methyl]biphenyl-2-sulfonamides as dual endothelin/angiotensin II receptor antagonists.

Tellew JE, Baska RA, Beyer SM, Carlson KE, Cornelius LA, Fadnis L, Gu Z, Kunst BL, Kowala MC, Monshizadegan H, Murugesan N, Ryan CS, Valentine MT, Yang Y, Macor JE.

Bioorg Med Chem Lett. 2003 Mar 24;13(6):1093-6.

PMID:
12643919
40.

Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective antagonist.

Murugesan N, Gu Z, Spergel S, Young M, Chen P, Mathur A, Leith L, Hermsmeier M, Liu EC, Zhang R, Bird E, Waldron T, Marino A, Koplowitz B, Humphreys WG, Chong S, Morrison RA, Webb ML, Moreland S, Trippodo N, Barrish JC.

J Med Chem. 2003 Jan 2;46(1):125-37.

PMID:
12502366
41.

Discovery of N-isoxazolyl biphenylsulfonamides as potent dual angiotensin II and endothelin A receptor antagonists.

Murugesan N, Tellew JE, Gu Z, Kunst BL, Fadnis L, Cornelius LA, Baska RA, Yang Y, Beyer SM, Monshizadegan H, Dickinson KE, Panchal B, Valentine MT, Chong S, Morrison RA, Carlson KE, Powell JR, Moreland S, Barrish JC, Kowala MC, Macor JE.

J Med Chem. 2002 Aug 29;45(18):3829-35.

PMID:
12190306
42.

Biphenylsulfonamide endothelin receptor antagonists. Part 3: structure-activity relationship of 4'-heterocyclic biphenylsulfonamides.

Murugesan N, Gu Z, Stein PD, Spergel S, Bisaha S, Liu EC, Zhang R, Webb ML, Moreland S, Barrish JC.

Bioorg Med Chem Lett. 2002 Feb 25;12(4):517-20.

PMID:
11844662
43.

Biphenylsulfonamide endothelin receptor antagonists. 2. Discovery of 4'-oxazolyl biphenylsulfonamides as a new class of potent, highly selective ET(A) antagonists.

Murugesan N, Gu Z, Stein PD, Spergel S, Mathur A, Leith L, Liu EC, Zhang R, Bird E, Waldron T, Marino A, Morrison RA, Webb ML, Moreland S, Barrish JC.

J Med Chem. 2000 Aug 10;43(16):3111-7.

PMID:
10956219
44.

Biphenylsulfonamide endothelin antagonists: structure-activity relationships of a series of mono- and disubstituted analogues and pharmacology of the orally active endothelin antagonist 2'-amino-N- (3,4-dimethyl-5-isoxazolyl)-4'-(2-methylpropyl)[1, 1'-biphenyl]-2-sulfonamide (BMS-187308).

Murugesan N, Gu Z, Stein PD, Bisaha S, Spergel S, Girotra R, Lee VG, Lloyd J, Misra RN, Schmidt J, Mathur A, Stratton L, Kelly YF, Bird E, Waldron T, Liu EC, Zhang R, Lee H, Serafino R, Abboa-Offei B, Mathers P, Giancarli M, Seymour AA, Webb ML, Hunt JT, et al.

J Med Chem. 1998 Dec 17;41(26):5198-218.

PMID:
9857090
45.

The discovery of sulfonamide endothelin antagonists and the development of the orally active ETA antagonist 5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulf onamide.

Stein PD, Hunt JT, Floyd DM, Moreland S, Dickinson KE, Mitchell C, Liu EC, Webb ML, Murugesan N, Dickey J, et al.

J Med Chem. 1994 Feb 4;37(3):329-31. No abstract available.

PMID:
8308857
46.

Chemistry of the alkali-labile lesion formed from iron(II) bleomycin and d(CGCTTTAAAGCG).

Sugiyama H, Xu C, Murugesan N, Hecht SM, van der Marel GA, van Boom JH.

Biochemistry. 1988 Jan 12;27(1):58-67.

PMID:
2450572
47.

Hemodialysis using single lumen subclavian catheter and double blood pump--an initial experience.

Murugesan N, Gowdle CP, Durgaprasad P, Ramalingam KS, Mani MK.

J Assoc Physicians India. 1987 Sep;35(9):619-21. No abstract available.

PMID:
3436929
48.

Analysis of products formed during bleomycin-mediated DNA degradation.

Murugesan N, Xu C, Ehrenfeld GM, Sugiyama H, Kilkuskie RE, Rodriguez LO, Chang LH, Hecht SM.

Biochemistry. 1985 Oct 8;24(21):5735-44.

PMID:
2417619
49.

Oxygen transfer from bleomycin-metal complexes.

Murugesan N, Ehrenfeld GM, Hecht SM.

J Biol Chem. 1982 Aug 10;257(15):8600-3.

Supplemental Content

Loading ...
Support Center